Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

It's been a while since Clarkson nabbed a movie role as full-scale and invigorating as the one she has in "Lilly," a ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Writer and director Rachel Feldman reflects on her heroine Lilly Ledbetter and all the mothers that helped bring her biopic ...

The Oscar-nominated actress talks about playing the activist whose 1990s lawsuit demanding equal pay with her male colleagues went all the way to the Supreme Court, and how her own mother inspired her ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly (NYSE:LLY) said Thursday that Ilya Yuffa, executive vice president and president, Lilly International, will become ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...